Background: One-third of men with type 2 diabetes have subnormal testosterone concentrations along with inappropriately normal LH and FSH concentrations. It is not known if the presence of renal insufficiency affects free testosterone concentrations in men with type 2 diabetes. Hypothesis: We hypothesized that type 2 diabetic men with chronic renal disease (CKD; estimated glomerular filtration rate (eGFR) !60 ml/min per 1.73 m 2 ) have lower free testosterone concentrations than men with normal renal function
free T. This is important because half of the total T in serum is bound to sex hormone binding globulin (SHBG). SHBG concentrations are lower in individuals with obesity and type 2 diabetes, which would lower total T concentrations (3) . Thus measurement of free T concentrations is necessary to accurately assess gonadal status in these patients (5) . The subnormal free T concentrations in type 2 diabetes are associated with low-normal or normal luteinizing hormone (LH) and follicle-stimulating hormone (FSH) concentrations and a high prevalence of symptoms suggestive of hypogonadism (2, 6) . Hence, this common syndrome can be termed hypogonadotropic hypogonadism (HH).
Of all, 10.6% of patients with type 2 diabetes have chronic kidney disease (estimated glomerular filtrate rate (eGFR) !60 ml/min per 1.73 m 2 ) (7). Total T concentrations are decreased in men with chronic kidney disease (CKD) (8, 9, 10, 11, 12, 13) . Endocrine society considers CKD and type 2 diabetes as conditions associated with a high prevalence of low T concentrations (5) . However, no study has documented the prevalence of subnormal free T concentrations in type 2 diabetic men with CKD. Neither is it well understood whether the subnormal T concentrations in CKD are associated with elevated, normal or subnormal gonadotropin concentrations. It is our clinical practice to measure T concentrations on all men with type 2 diabetes. This is consistent with the Endocrine Society guidelines (5) . To perform a comprehensive assessment, we measure T (total and free), SHBG, LH, FSH and prolactin concentrations. We hypothesized that type 2 diabetic men with CKD will have a higher prevalence of subnormal free T concentrations as compared to men without CKD. We present data on T and gonadotropin concentrations in 111 men with type 2 diabetes and CKD (stages 3-5) and 182 type 2 diabetic men without CKD.
Subjects and methods
This is a retrospective chart review that includes the charts of all adult (age O18 years) male patients attending the following clinics between January 2012 and December 2014: diabetes clinics at Texas Tech University Health Sciences Center-Permian Basin, Odessa, Texas and the Diabetes-Endocrinology Center of Western New York, State University of New York, Buffalo, New York, and the nephrology clinic at the Permian Basin Kidney Center, Odessa, Texas.
Patients who had the following information available were included in a password-locked database -T (total and free) done by liquid chromatography tandem mass spectrometry (LC-MS/MS) followed by equilibrium dialysis, SHBG, LH, FSH and prolactin concentrations. Exclusion criteria were panhypopituitarism or congenital HH; severe depression or psychiatric illness; head trauma, hemochromatosis, cirrhosis, hepatitis C or HIV; treatment with testosterone, steroids, or opiates; treatment with medications that can cause hyperprolactinemia; patients with active infection or who had a recent surgery or hospitalization for any reason in the last 6 weeks. HIPAA forms were signed by all patients. The collected data was kept confidential by the investigators and patient identifiers were eliminated from the database once the master database had been created. Permission was obtained to review patient charts to collect data from the Institutional Review Board of the Texas Tech University of Health Sciences Center.
All patients had provided fasting blood samples between 0800 and 1000 h to measure serum T, SHBG, LH, FSH and prolactin. The measurements were carried out by a commercial laboratory. T concentrations were measured by LC-MS/MS and free T was separated by tracer equilibrium dialysis method (14) . The sensitivity of the assay, set at a coefficient of variation (CV) of %20%, was 0.3 ng/dl. The intra-assay CV ranged from 7.6 to 10.8% and inter-assay CV ranged from 9.8 to 13.4% at total T concentrations between 0.34 and 41.67 nmol/l. Reference range for total T (8.7-38.2 nmol/l) and free T (0.17-0.87 nmol/l) was determined from 264 apparently healthy men by the laboratory. SHBG (normal range 13-1 nmol/l), LH (normal range 2-10 IU/l), FSH (normal range 2-8 IU/l) and prolactin (normal range 0.09-0.78 nmol/l) concentrations were measured by a solid-phase, immunochemiluminometric assays (ADVIA Centaur). The analytical sensitivity for SHBG by this assay was 2 nmol/l. The intra-assay CV was 6.2% at SHBG concentration of 4.14 nmol/l and 3.2% at 66.9 nmol/l. The inter-assay CV was 4.1% at 4.14 nmol/l and 5.2% at 66.9 nmol/l. CKD stages were defined based on eGFR by the CKD-EPI (CKD Epidemiology Collaboration) equation (15 , we adjusted T and SHBG concentrations as well as prevalence of low T for age and BMI differences when comparing groups. In addition, total T concentrations were adjusted for SHBG differences. Data are presented as meansGS.D. for normally distributed data and median (25th, 75th percentile) for non-normal data. P!0.05 was considered significant.
Results
We screened charts of 451 men with type 2 diabetes for availability of relevant laboratory data. Forty-two men were excluded because they did not satisfy the study inclusion and exclusion criteria. Commonest reasons for exclusion were hepatitis C, panhypopituitarism or treatment with testosterone. We excluded 116 men because their T concentrations were measured by inaccurate assays or because hormonal measurements were missing. Out of 293 men with type 2 diabetes that qualified for the study, 111 had CKD and 182 had normal eGFR. Seven percent of men with CKD were African Americans, 61% were Caucasian, 25% were Hispanic and 7% identified themselves as 'other.' Eight percent of men without CKD were African Americans, 63% were Caucasian, 21% were Hispanic and 8% identified themselves as 'other' (PZ0.97 for comparison with CKD group).
Comparison of hormone concentrations in men with and without CKD
Men with CKD were older than men without CKD while their BMI tended to be lower (Table 1) . Men with CKD had diabetes for a longer duration than men without CKD. Higher proportion of CKD patients had insulin as part of their diabetes regimen while their use of metformin and sulfonylureas was lower than that by patients without CKD. Free T concentrations were related inversely to age (bZK0.35, P!0.001) and BMI (bZK0.23, P!0.001) but not to duration of diabetes (bZK0.05, PZ0.39). Therefore, we adjusted T concentrations for differences in age and BMI among men with and without CKD ( Table 1) .
Total and free T concentrations were lower in men with CKD. The median gonadotropin concentrations were higher in men with CKD as compared to men with normal eGFR. Consistent with this, men with CKD had a higher prevalence of hypergonadotropic hypogonadism but not of HH. Table 2 depicts the hormone concentrations of men with CKD and hypogonadotropic, hypergonadotropic or compensated hypogonadism. Men with HH had higher BMI than other groups. The free T concentrations of men with compensated hypogonadism were lower than eugonadal men but higher than those with hypogonadotropic or hypergonadotropic hypogonadism.
As expected, men with CKD had lower hemoglobin concentrations than men without CKD (Table 1 ). In men without CKD, the hemoglobin concentrations were lower in those with subnormal free T concentrations as compared to men with normal free T concentrations (139G13 vs 144G10 g/l, PZ0.02). Similarly, in men with CKD, the hemoglobin concentrations were lower in those with subnormal free T concentrations as compared to men with normal free T concentrations (119G19 vs 128G 19 g/l, PZ0.04). Hemoglobin concentrations were positively related to eGFR (rZ0.61, P!0.001) and to free T concentrations (rZ0.31, P!0.001), and inversely related for comparison across groups. SHBG, free T concentrations, prevalence of subnormal free T and prevalence of cardiovascular disease were adjusted for age and BMI differences between groups. Total T concentrations were adjusted for age, BMI and SHBG differences. To convert T into SI units (nmol/l), divide by 28.8. Data are presented as meansGS.D.
for normally distributed data and median (25th, 75th percentile) for non-normal data. SHBG concentrations were not normally distributed and are presented as reverse log-transformed values after adjustment for age and BMI. Five men in CKD stage 5 were on erythropoietin; hence, their hemoglobin concentrations were not included in the study. *P!0.05 as compared to normal eGFR category and to age (rZK0.17, PZ0.01). In multivariate regression analyses, both eGFR (bZ0.60, P!0.001) and free T concentrations (bZ0.21, PZ0.001) were predictors of hemoglobin concentrations, but age was not (bZ0.10, PZ0.13).
Comparison across CKD stages
We then compared the hormone concentrations of men in CKD stages 3, 4 or 5 with those of men without CKD (Table 1 ). There was a progressive decline in T concentrations and an increase in the prevalence of subnormal free T concentrations with worsening renal insufficiency. This was accompanied by an increase in LH, FSH and prolactin concentrations. While there was no change in the prevalence of HH, there was an increase in the prevalence of hypergonadotropic hypogonadism with worsening CKD. Approximately half of all men with renal failure (CKD stage 5) had hypergonadotropic hypogonadism.
There was an increase in prolactin concentrations with worsening CKD. The prevalence of supranormal prolactin concentrations (O0.78 nmol/l) was 3% in men with normal eGFR, 3% in CKD stage 3, 11% in CKD stage 4 and 27% in CKD stage 5 (PZ0.001 for comparison by c 2 across groups). The prevalence of HH was similar in men with and without hyperprolactinemia (25% vs 47%, PZ0.24). Hyperprolactinemia O1.3 nmol/l was not detected in any patient with normal eGFR and CKD stage 3. Prolactinemia above 1.3 nmol/l was present in one patient with stage 4 CKD. His prolactin concentration was 1.6 nmol/l and he had normal free T concentrations. Hyperprolactinemia was present in four patients with stage 5 CKD (prolactin concentrations were 1.4, 1.9, 2.3, 3.4 nmol/l). All four patients had low free T concentrations; two patients were hypogonadotropic and two were hypergonadotropic. All patients with prolactin concentrations O1.3 nmol/l were evaluated by an endocrinologist and were not found to have a prolactinoma.
There was a progressive decrease in hemoglobin concentrations across progression of CKD stages (Table 1) . Thirteen percent of all patients with CKD had hemoglobin concentrations !100 g/l (the threshold for use of erythropoietin in clinical practice). Only one patient with hemoglobin !10 g/dl had normal free T concentrations. The rest of these patients had subnormal free T concentrations.
We also compared the T concentrations of men without CKD but with or without albuminuria. Eighteen percent of men without CKD had micro-albuminuria and 3% had macro-albuminuria. The total and free T concentrations were similar in men with and without albuminuria (13.16G7.01 and 12.53G5.14 nmol/l for total T, PZ0.64; 0.21G0.09 and 0.19G0.18 nmol/l for free T, PZ0.75).
Discussion
We have shown that two-thirds of men with CKD and type 2 diabetes have low free T concentrations. Another 10% had compensated hypogonadism, a condition that is likely to convert into hypergonadotropic hypogonadism in the future (16) . Thus, only 24% of men with CKD had normal T and LH concentrations. The situation was particularly dismal in stages 4 and 5, in which w90% of men were either hypogonadal and/or had compensated hypogonadism.
Our study is also the first to comprehensively describe the prevalence of hypogonadotropic, hypergonadotropic and compensated hypogonadism in CKD. We found that the prevalence of HH in men with type 2 diabetes was similar across all stages of CKD (range: 32-46%). This is consistent with the prevalence described in type 2 diabetic men without CKD (2, 3, 6) . In contrast, we found that the prevalence of hypergonadotropic hypogonadism increased with worsening CKD. The median gonadotropin concentrations of men with CKD stage 5 were two to three times higher than men with normal eGFR. Studies that have measured gonadotropin concentrations in men with CKD stage 5 have also reported similarly high gonadotropin concentrations (17, 18, 19) . Deconvolution analyses of frequently measured LH concentrations over 24 h have shown that the half life of LH is doubled, but the daily secretion rate of LH is lower by 50% in eugonadal men with CKD as compared to healthy men (20) . This results in 58% higher mean LH concentrations over 24 h in men with CKD. However, the T concentrations of men with CKD in our study were lower in spite of the higher circulating LH concentrations. Men with renal failure also have decreased spermatogenesis, infertility and decreased concentrations of anti-mullerian hormone (8, 17) . Thus, there is evidence of both leydig cell and sertoli cell dysfunction in men with renal failure. It is possible that CKD is associated with an increase in inactive LH fragments in the circulation. There are data to suggest that immunoreactive but biologically inactive LH fragments may be increased in renal failure (21, 22) . We did not measure LH bioactivity in our patients. It is possible that a portion of LH concentrations in our patients with renal failure is not bioactive and that some men with hypergonadotropic hypogonadism may actually have HH (23) . Similarly, some men with compensated hypogonadism may be eugonadal. However, we found that the T concentrations of men with compensated hypogonadism were lower than those of eugonadal men (Table 2 ). This suggests that LH concentrations in these men were appropriately elevated as a result of decreased T concentrations and not because they are inactive metabolites that have accumulated due to decreased clearance in CKD.
Chronic renal failure is associated with an increase in prolactin concentrations (24, 25) . Decreased clearance and increased production are responsible for the elevation of prolactin in CKD (26) . Consistent with other studies, we found higher prolactin concentrations in patients with CKD (17) . However, the mild elevations in prolactin had no impact on the prevalence of HH. Neither was there any difference in prolactin concentrations among men with hypogonadotropic or hypergonadotropic hypogonadism ( Table 2 ). The hyperprolactinemia in renal failure is not corrected by dialysis. Nor is it likely that hemodialysis is responsible for the low T concentrations in CKD, because the clearance of T by hemodialysis is miniscule (27) .
Prior studies have found that total T concentrations are frequently low in men with renal failure. Studies in hemodialysis patients have reported that 44-57% of the men have subnormal total T concentrations (12, 13, 28) . In one study of 239 patients referred to a renal center, the prevalence of subnormal total T concentrations was 17, 17, 34, 38 and 57% in CKD stages 1-5 respectively (10). In a large study of 2419 patients with CKD stage 3 or 4, 53% were found to have subnormal total T concentrations (11) . However, half of these patients had their blood sample drawn in the afternoon. Since T concentrations can decline by 30% as the day progresses, this would falsely increase the prevalence of subnormal T concentrations. Overall, the literature suggests that approximately half of men with ESRD have low total T concentrations and approximately one-third of men with milder forms of renal failure have low total T. These studies also found that the total T concentrations were lower in men with type 2 diabetes and CKD as compared to men without diabetes and CKD (10, 11, 12, 29) . These studies have used immunoassays to measure total T concentrations in men with CKD. Immunoassays have poor accuracy at lower T concentrations and are not recommended for assessment of hypogonadism. The recommended assay to measure total T is LC-MS/MS. Only one study has reported total T concentrations measured by LC-MS/MS in men with CKD (29) . However, there was no comparison group of men with normal eGFR, nor was the prevalence of subnormal total T concentrations mentioned. Free T concentrations were not reported. Ours is the only study in men with CKD that has measured total and free T by the recommended 'gold-standard methodology': LC-MS/MS and equilibrium dialysis (5) .
We found that subnormal free T concentrations were associated with lower hemoglobin concentrations. This is consistent with the known erythropoietic effect of testosterone. We have previously shown that hemoglobin concentrations are lower in hypogonadal type 2 diabetic men without CKD (30) . Our current data indicate that this is true in type 2 diabetic men with CKD as well. One previous study has also found that total T concentrations are related to hemoglobin concentrations in men with CKD (31) . Furthermore, almost all men with hemoglobin concentrations !100 g/l had subnormal free T concentrations. It is well known that decreased erythropoietin concentrations are largely responsible for renal failure-associated anemia. Since we excluded CKD patients who were on erythropoietin, we cannot comment on the relative contributions of erythropoietin and testosterone on hemoglobin concentrations in CKD. Neither is it known if T replacement therapy to normalize the T concentrations would decrease the need of erythropoietin therapy in anemic men with CKD (32, 33) .
It is well known that there is significant day-to-day variability in hormone concentrations, especially testosterone. As in most epidemiologic or cross-sectional studies, the hormone concentrations were measured only once in this study. In view of the variability in testosterone concentrations, this is a limitation. However, it is not likely that the prevalence of subnormal free testosterone concentrations would have altered following repeated measurements since the probability of testosterone concentrations rising or falling with repeated measurements is statistically equal. The issue of repeated measurements is important in the context of diagnosing hypogonadism clinically in individual patients. The fact that our study included a moderately large number of participants also helps to diminish the effect of hormonal variability on study results.
Another limitation of our study was that we did not collect data on signs or symptoms of hypogonadism in patients. There is a high prevalence of symptoms of hypogonadism in men with renal failure (34, 35, 36) . Many of the signs and symptoms of hypogonadism such as erectile dysfunction, fatigue, anemia, poor quality of life, sarcopenia and low bone mass are also believed to be a consequence of renal failure (37) . This limits the predictive value of screening for signs and symptoms of hypogonadism in men with CKD. This probably explains why very few CKD patients (12% in one study) have their T concentrations tested for clinical indications (11, 37) . It is possible that T replacement therapy will improve sexual symptoms, fatigue, anemia, muscle mass and bone mass in hypogonadal men with CKD. The role of T in men with CKD needs to be thoroughly evaluated. This is imperative, since low total T concentrations have been consistently associated with increased mortality in men with CKD (11, 29) . Whether T is a marker or mediator of mortality in men with CKD can only be answered through trials of T replacement.
In summary, we have demonstrated that two-thirds of men with type 2 diabetes and CKD have subnormal free T concentrations. As shown in prior studies (1, 2, 4), we found that approximately one-third of men with type 2 diabetes have HH. This was consistent across all stages of CKD. The presence of CKD was additionally associated with an increase in the prevalence of hypergonadotropic hypogonadism and compensated hypogonadism in men with type 2 diabetes. Subnormal free T concentrations were associated with lower hemoglobin concentrations in men with CKD.
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